American Bio Medica Corporation (ABMC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 3.6 Million USD | 27.63% |
| 2021 | 2.82 Million USD | -11.16% |
| 2020 | 3.18 Million USD | 10.95% |
| 2019 | 2.86 Million USD | 9.42% |
| 2018 | 2.62 Million USD | 15.56% |
| 2017 | 2.26 Million USD | -3.32% |
| 2016 | 2.34 Million USD | -17.28% |
| 2015 | 2.83 Million USD | -8.75% |
| 2014 | 3.1 Million USD | -14.33% |
| 2013 | 3.62 Million USD | 6.24% |
| 2012 | 3.41 Million USD | 4.56% |
| 2011 | 3.26 Million USD | -2.74% |
| 2010 | 3.35 Million USD | -8.3% |
| 2009 | 3.66 Million USD | -24.93% |
| 2008 | 4.87 Million USD | 20.33% |
| 2007 | 4.05 Million USD | 36.04% |
| 2006 | 2.98 Million USD | 24.95% |
| 2005 | 2.38 Million USD | -5.99% |
| 2004 | 2.53 Million USD | 25.84% |
| 2003 | 2.01 Million USD | -13.4% |
| 2002 | 2.32 Million USD | -14.82% |
| 2001 | 2.73 Million USD | 49.59% |
| 2000 | 1.82 Million USD | 24.97% |
| 1999 | 1.46 Million USD | 192.4% |
| 1998 | 500 Thousand USD | 31.53% |
| 1997 | 380.15 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 1.11 Million USD | -69.04% |
| 2023 Q2 | - USD | -100.0% |
| 2022 FY | 3.6 Million USD | 27.63% |
| 2022 Q1 | 2.87 Million USD | 1.63% |
| 2022 Q2 | 2.96 Million USD | 3.17% |
| 2022 Q3 | 3.19 Million USD | 7.93% |
| 2022 Q4 | 3.6 Million USD | 12.79% |
| 2021 FY | 2.82 Million USD | -11.16% |
| 2021 Q1 | 3.19 Million USD | 0.5% |
| 2021 Q2 | 3.13 Million USD | -1.91% |
| 2021 Q3 | 3 Million USD | -4.34% |
| 2021 Q4 | 2.82 Million USD | -5.8% |
| 2020 Q4 | 3.18 Million USD | 5.33% |
| 2020 FY | 3.18 Million USD | 10.95% |
| 2020 Q2 | 3.19 Million USD | -13.98% |
| 2020 Q3 | 3.02 Million USD | -5.39% |
| 2020 Q1 | 3.71 Million USD | 29.43% |
| 2019 Q2 | 2.58 Million USD | -3.69% |
| 2019 FY | 2.86 Million USD | 9.42% |
| 2019 Q1 | 2.68 Million USD | 2.37% |
| 2019 Q4 | 2.86 Million USD | 2.1% |
| 2019 Q3 | 2.8 Million USD | 8.71% |
| 2018 Q1 | 2.49 Million USD | 10.19% |
| 2018 Q3 | 2.74 Million USD | 8.2% |
| 2018 Q2 | 2.53 Million USD | 1.56% |
| 2018 Q4 | 2.62 Million USD | -4.55% |
| 2018 FY | 2.62 Million USD | 15.56% |
| 2017 Q4 | 2.26 Million USD | -0.83% |
| 2017 Q1 | 2.37 Million USD | 1.15% |
| 2017 Q3 | 2.28 Million USD | 2.1% |
| 2017 FY | 2.26 Million USD | -3.32% |
| 2017 Q2 | 2.24 Million USD | -5.6% |
| 2016 Q1 | 2.51 Million USD | -11.39% |
| 2016 Q3 | 2.37 Million USD | -4.93% |
| 2016 Q4 | 2.34 Million USD | -1.05% |
| 2016 FY | 2.34 Million USD | -17.28% |
| 2016 Q2 | 2.49 Million USD | -0.76% |
| 2015 FY | 2.83 Million USD | -8.75% |
| 2015 Q4 | 2.83 Million USD | -7.29% |
| 2015 Q1 | 3.02 Million USD | -2.67% |
| 2015 Q2 | 3.27 Million USD | 8.36% |
| 2015 Q3 | 3.05 Million USD | -6.68% |
| 2014 Q1 | 3.36 Million USD | -7.33% |
| 2014 FY | 3.1 Million USD | -14.33% |
| 2014 Q2 | 3.04 Million USD | -9.58% |
| 2014 Q3 | 3.14 Million USD | 3.29% |
| 2014 Q4 | 3.1 Million USD | -1.02% |
| 2013 FY | 3.62 Million USD | 6.24% |
| 2013 Q1 | 3.89 Million USD | 14.08% |
| 2013 Q2 | 4.27 Million USD | 9.68% |
| 2013 Q3 | 3.72 Million USD | -12.73% |
| 2013 Q4 | 3.62 Million USD | -2.71% |
| 2012 FY | 3.41 Million USD | 4.56% |
| 2012 Q1 | 3.52 Million USD | 7.87% |
| 2012 Q3 | 3.8 Million USD | -0.68% |
| 2012 Q2 | 3.83 Million USD | 8.71% |
| 2012 Q4 | 3.41 Million USD | -10.23% |
| 2011 Q4 | 3.26 Million USD | -7.22% |
| 2011 FY | 3.26 Million USD | -2.74% |
| 2011 Q3 | 3.52 Million USD | 0.34% |
| 2011 Q2 | 3.5 Million USD | -5.06% |
| 2011 Q1 | 3.69 Million USD | 10.04% |
| 2010 Q2 | 3.95 Million USD | -0.58% |
| 2010 Q3 | 3.83 Million USD | -2.86% |
| 2010 Q1 | 3.97 Million USD | 8.55% |
| 2010 Q4 | 3.35 Million USD | -12.53% |
| 2010 FY | 3.35 Million USD | -8.3% |
| 2009 Q4 | 3.66 Million USD | -9.91% |
| 2009 Q1 | 5.15 Million USD | 5.68% |
| 2009 Q2 | 4.8 Million USD | -6.87% |
| 2009 Q3 | 4.06 Million USD | -15.33% |
| 2009 FY | 3.66 Million USD | -24.93% |
| 2008 FY | 4.87 Million USD | 20.33% |
| 2008 Q3 | 4.94 Million USD | 15.12% |
| 2008 Q1 | 4.42 Million USD | 9.1% |
| 2008 Q4 | 4.87 Million USD | -1.41% |
| 2008 Q2 | 4.29 Million USD | -2.83% |
| 2007 Q2 | 3.96 Million USD | 5.4% |
| 2007 Q4 | 4.05 Million USD | -0.44% |
| 2007 FY | 4.05 Million USD | 36.04% |
| 2007 Q1 | 3.75 Million USD | 26.07% |
| 2007 Q3 | 4.07 Million USD | 2.83% |
| 2006 Q2 | 2.07 Million USD | -3.89% |
| 2006 Q1 | 2.16 Million USD | -9.35% |
| 2006 Q3 | 2.46 Million USD | 18.82% |
| 2006 Q4 | 2.98 Million USD | 20.7% |
| 2006 FY | 2.98 Million USD | 24.95% |
| 2005 Q2 | 1.98 Million USD | 5.7% |
| 2005 FY | 2.38 Million USD | -5.99% |
| 2005 Q4 | 2.38 Million USD | 5.58% |
| 2005 Q1 | 1.87 Million USD | -26.01% |
| 2005 Q3 | 2.25 Million USD | 13.86% |
| 2004 Q2 | 1.88 Million USD | -10.43% |
| 2004 Q1 | 2.09 Million USD | 4.12% |
| 2004 Q3 | 2.18 Million USD | 16.17% |
| 2004 Q4 | 2.53 Million USD | 16.16% |
| 2004 FY | 2.53 Million USD | 25.84% |
| 2003 FY | 2.01 Million USD | -13.4% |
| 2003 Q1 | 2.45 Million USD | 5.28% |
| 2003 Q3 | 2.78 Million USD | 32.26% |
| 2003 Q4 | 2.01 Million USD | -27.69% |
| 2003 Q2 | 2.1 Million USD | -13.99% |
| 2002 FY | 2.32 Million USD | -14.82% |
| 2002 Q2 | 2.49 Million USD | -1.19% |
| 2002 Q4 | 2.32 Million USD | -3.36% |
| 2002 Q1 | 2.52 Million USD | 0.0% |
| 2002 Q3 | 2.4 Million USD | -3.49% |
| 2001 Q2 | 2.58 Million USD | 6.39% |
| 2001 Q3 | 1.37 Million USD | -46.9% |
| 2001 Q1 | 2.42 Million USD | 32.19% |
| 2001 FY | 2.73 Million USD | 49.59% |
| 2000 Q1 | 1.82 Million USD | -21.49% |
| 2000 Q3 | 2.01 Million USD | 8.4% |
| 2000 Q2 | 1.85 Million USD | 1.64% |
| 2000 FY | 1.82 Million USD | 24.97% |
| 2000 Q4 | 1.83 Million USD | -8.79% |
| 1999 Q3 | 1.74 Million USD | 24.79% |
| 1999 Q2 | 1.4 Million USD | -4.24% |
| 1999 Q1 | 1.46 Million USD | 112.81% |
| 1999 FY | 1.46 Million USD | 192.4% |
| 1999 Q4 | 2.32 Million USD | 33.2% |
| 1998 Q4 | 687 Thousand USD | -41.48% |
| 1998 Q3 | 1.17 Million USD | 254.68% |
| 1998 Q2 | 331 Thousand USD | -33.8% |
| 1998 Q1 | 500 Thousand USD | 400.0% |
| 1998 FY | 500 Thousand USD | 31.53% |
| 1997 FY | 380.15 Thousand USD | 0.0% |
| 1997 Q4 | 100 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Arrayit Corporation | 7.49 Million USD | 51.871% |
| Atlantic International Corp. | 3.82 Million USD | 5.762% |
| Biocept, Inc. | 22.01 Million USD | 83.61% |
| Bioqual, Inc. | 18.93 Million USD | 80.948% |
| CardioGenics Holdings Inc | 1.79 Million USD | -101.011% |
| DermTech, Inc. | 64.75 Million USD | 94.428% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.509% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 70.87% |
| iMD Companies, Inc. | 1.67 Million USD | -115.504% |
| IDenta Corp. | 1.01 Million USD | -256.114% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 87.186% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -1110.954% |
| InVitro International | 78.99 Thousand USD | -4467.667% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 81.712% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -2690.475% |
| Medical Imaging Corp. | 9.51 Million USD | 62.089% |
| NovelStem International Corp. | 4.2 Million USD | 14.219% |
| Optigenex Inc. | 9.57 Million USD | 62.301% |
| PharmChem, Inc. | 558.64 Thousand USD | -545.846% |
| Proteome Sciences plc | 18.48 Million USD | 80.486% |
| Response Genetics, Inc | 15.86 Million USD | 77.261% |
| Rennova Health, Inc. | 49.66 Million USD | 92.736% |
| RushNet, Inc. | 6.23 Million USD | 42.17% |
| ScreenPro Security Inc. | 1.6 Million USD | -125.417% |
| Stella Diagnostics Inc. | 18 Million USD | 79.962% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 56.021% |
| Todos Medical Ltd. | 50.15 Million USD | 92.807% |